Yuan-Kai Shi (Yuankai Shi)

ORCID

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 47

Top Venues

Thoracic cancer

Epigenomics

Cancer immunology, immunotherapy : CII

Immunotherapy

This page only lists publications with an associated author ORCID identifier.

Publications

Yu Zhou, Haizhu Chen, Le Tang, Yu Feng, Yunxia Tao, Liling Huang, Ning Lou, Yuan-Kai Shi
Association of immune-related adverse events and efficacy in advanced non-small-cell lung cancer: a systematic review and meta-analysis. Immunotherapy 15 (3) (2023)
Yu Zhou, Haizhu Chen, Le Tang, Yu Feng, Yunxia Tao, Liling Huang, Ning Lou, Yuan-Kai Shi
Association of immune-related adverse events and efficacy in advanced non-small-cell lung cancer: a systematic review and meta-analysis. Immunotherapy 15 (3) (2023)
Liyuan Dai, Haizhu Chen, Qiaoyun Tan, Yanrong Wang, Lin Li, Ning Lou, Guangyu Fan, Tongji Xie, Rongrong Luo, Shasha Wang, Yu Zhou, Qiaofeng Zhong, Jiarui Yao, Zhishang Zhang, Le Tang, Yuan-Kai Shi, Xiao-Hong Han
Identification of novel prognostic autoantibodies in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone via a high-throughput antigen microarray. Cancer (2023)
Yuan-Kai Shi, Jie Cui, Hui Zhou, Xiaohong Zhang, Liqun Zou, Junning Cao, Yuhuan Gao, Chuan Jin, Xiaoling Li, Hui Liu, Zhigang Peng, Liping Xie, Huilai Zhang, Weihua Zhang, Hongyu Zhang, Liye Zhong, Fang Zhou, Genny Guo, Wenduo He
Efficacy and safety of geptanolimab (GB226) for relapsed/refractory primary mediastinal large B-cell lymphoma: an open-label phase II study (Gxplore-003). Cancer immunology, immunotherapy : CII (2023)
Tongji Xie, Guangyu Fan, Liling Huang, Ning Lou, Xiao-Hong Han, Pu-Yuan Xing, Yuan-Kai Shi
Analysis on methylation and expression of PSMB8 and its correlation with immunity and immunotherapy in lung adenocarcinoma. Epigenomics 14 (22) (2023)
Yu Feng, Yunxia Tao, Haizhu Chen, Yu Zhou, Le Tang, Chenwei Liu, Xing-Sheng Hu, Yuan-Kai Shi
Efficacy and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer: A systematic review and meta-analysis. Thoracic cancer (2023)
Xingsheng Hu, Shucai Zhang, Zhiyong Ma, Jifeng Feng, Lin Wu, Dongqing Lv, Jianying Zhou, Xiaodong Zhang, Li Liu, Qitao Yu, Wangjun Liao, Yiping Zhang, Xiang Wang, Ying Cheng, Hongrui Niu, Ziping Wang, Dong Wang, Cheng Huang, Chunling Liu, Hui Zhao, Jian Feng, Jingzhang Li, Kejing Ying, Nong Yang, Shukui Qin, Jie Hu, Fei Liu, Yong Jiang, Nan Ge, Yuan-Kai Shi
Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studies. BMC medicine 21 (1) (2023)
Tongji Xie, Guangyu Fan, Liling Huang, Ning Lou, Xiao-Hong Han, Pu-Yuan Xing, Yuan-Kai Shi
Analysis on methylation and expression of PSMB8 and its correlation with immunity and immunotherapy in lung adenocarcinoma. Epigenomics 14 (22) (2023)
Mingzhao Wang, Jun Zhao, Tong Chen, Xing-Sheng Hu, Lin Wang, Yuan-Kai Shi, Yutao Liu
Efficacy and safety of osimertinib plus anlotinib in advanced non-small-cell lung cancer patients after drug resistance. Thoracic cancer (2023)
Yu Zhou, Haizhu Chen, Le Tang, Yu Feng, Yunxia Tao, Liling Huang, Ning Lou, Yuan-Kai Shi
Association of immune-related adverse events and efficacy in advanced non-small-cell lung cancer: a systematic review and meta-analysis. Immunotherapy 15 (3) (2023)
Liyuan Dai, Haizhu Chen, Qiaoyun Tan, Yanrong Wang, Lin Li, Ning Lou, Guangyu Fan, Tongji Xie, Rongrong Luo, Shasha Wang, Yu Zhou, Qiaofeng Zhong, Jiarui Yao, Zhishang Zhang, Le Tang, Yuan-Kai Shi, Xiao-Hong Han
Identification of novel prognostic autoantibodies in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone via a high-throughput antigen microarray. Cancer 130 (8) (2023)
Qiaofeng Zhong, Haizhu Chen, Daoguang Chen, Yan Qin, Xiaohui He, Yu Yang, Jianliang Yang, Peng Liu, Shengyu Zhou, Sheng Yang, Yu Zhou, Le Tang, Chuanben Chen, Yuan-Kai Shi
Development and validation of a novel risk stratification model and a survival rate calculator for diffuse large B-cell lymphoma in the rituximab era: a multi-institutional cohort study. Annals of hematology (2023)
Xingsheng Hu, Shucai Zhang, Zhiyong Ma, Jifeng Feng, Lin Wu, Dongqing Lv, Jianying Zhou, Xiaodong Zhang, Li Liu, Qitao Yu, Wangjun Liao, Yiping Zhang, Xiang Wang, Ying Cheng, Hongrui Niu, Ziping Wang, Dong Wang, Cheng Huang, Chunling Liu, Hui Zhao, Jian Feng, Jingzhang Li, Kejing Ying, Nong Yang, Shukui Qin, Jie Hu, Fei Liu, Yong Jiang, Nan Ge, Yuan-Kai Shi
Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studies. BMC medicine 21 (1) (2023)
Tongji Xie, Guangyu Fan, Liling Huang, Ning Lou, Xiao-Hong Han, Pu-Yuan Xing, Yuan-Kai Shi
Analysis on methylation and expression of PSMB8 and its correlation with immunity and immunotherapy in lung adenocarcinoma. Epigenomics 14 (22) (2023)
Yu Zhou, Haizhu Chen, Le Tang, Yu Feng, Yunxia Tao, Liling Huang, Ning Lou, Yuan-Kai Shi
Association of immune-related adverse events and efficacy in advanced non-small-cell lung cancer: a systematic review and meta-analysis. Immunotherapy (2023)
Tongji Xie, Guangyu Fan, Liling Huang, Ning Lou, Xiao-Hong Han, Pu-Yuan Xing, Yuan-Kai Shi
Analysis on methylation and expression of PSMB8 and its correlation with immunity and immunotherapy in lung adenocarcinoma. Epigenomics 14 (22) (2023)
Liyuan Dai, Haizhu Chen, Qiaoyun Tan, Yanrong Wang, Lin Li, Ning Lou, Guangyu Fan, Tongji Xie, Rongrong Luo, Shasha Wang, Yu Zhou, Qiaofeng Zhong, Jiarui Yao, Zhishang Zhang, Le Tang, Yuan-Kai Shi, Xiao-Hong Han
Identification of novel prognostic autoantibodies in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone via a high-throughput antigen microarray. Cancer 130 (8) (2023)
Xingsheng Hu, Shucai Zhang, Zhiyong Ma, Jifeng Feng, Lin Wu, Dongqing Lv, Jianying Zhou, Xiaodong Zhang, Li Liu, Qitao Yu, Wangjun Liao, Yiping Zhang, Xiang Wang, Ying Cheng, Hongrui Niu, Ziping Wang, Dong Wang, Cheng Huang, Chunling Liu, Hui Zhao, Jian Feng, Jingzhang Li, Kejing Ying, Nong Yang, Shukui Qin, Jie Hu, Fei Liu, Yong Jiang, Nan Ge, Yuan-Kai Shi
Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studies. BMC medicine 21 (1) (2023)
Tongji Xie, Guangyu Fan, Liling Huang, Ning Lou, Xiao-Hong Han, Pu-Yuan Xing, Yuan-Kai Shi
Analysis on methylation and expression of PSMB8 and its correlation with immunity and immunotherapy in lung adenocarcinoma. Epigenomics (2023)
Xingsheng Hu, Shucai Zhang, Zhiyong Ma, Jifeng Feng, Lin Wu, Dongqing Lv, Jianying Zhou, Xiaodong Zhang, Li Liu, Qitao Yu, Wangjun Liao, Yiping Zhang, Xiang Wang, Ying Cheng, Hongrui Niu, Ziping Wang, Dong Wang, Cheng Huang, Chunling Liu, Hui Zhao, Jian Feng, Jingzhang Li, Kejing Ying, Nong Yang, Shukui Qin, Jie Hu, Fei Liu, Yong Jiang, Nan Ge, Yuan-Kai Shi
Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studies. BMC medicine 21 (1) (2023)
Liliang Huang, Yuankai Shi, Yuan-Kai Shi
Prognostic significance of baseline neutrophil-lymphocyte ratio in patients with non-small-cell lung cancer: a pooled analysis of open phase III clinical trial data. Future oncology (London, England) 18 (14) (2022)
Yuan-Kai Shi, Lin Wu, Xinmin Yu, Puyuan Xing, Yan Wang, Jianying Zhou, Airong Wang, Jianhua Shi, Yi Hu, Ziping Wang, Guangyu An, Yong Fang, Sanyuan Sun, Cai-Cun Zhou, Changli Wang, Feng Ye, Xingya Li, Junye Wang, Mengzhao Wang, Yunpeng Liu, Yanqiu Zhao, Ying Yuan, Jifeng Feng, Zhendong Chen, Jindong Shi, Tao Sun, Gang Wu, Yongqian Shu, Qisen Guo, Yi Zhang, Yong Song, Shucai Zhang, Yuan Chen, Wei Li, Hongrui Niu, Wenwei Hu, Lijun Wang, Jianan Huang, Yang Zhang, Ying Cheng, Zhengdong Wu, Bo Peng, Jiya Sun, Christoph Mancao, Yanqi Wang, Luyao Sun
Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3). Cancer communications (London, England) (2022)
Jun Zhu, Xiaonan Hong, Yu Qin Song, Brendan Hodkinson, Sriram Balasubramanian, Songbai Wang, Qingyuan Zhang, Yuan-Kai Shi, Huiqiang Huang, Huilai Zhang, Yan Zhu, Stephen Martin Shreeve, Steven Sun, Ze Wang, Xiaocan Wang, Yue Fan, Wyndham Wilson, Jessica Vermeulen
Ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone in patients with previously untreated non-germinal centre B-cell-like diffuse large B-cell lymphoma: A Chinese subgroup analysis of the phase III PHOENIX trial. EJHaem 3 (4) (2022)
Haizhu Chen, Yu Feng, Yu Zhou, Yunxia Tao, Le Tang, Yuan-Kai Shi
Brain metastases and immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis. Cancer immunology, immunotherapy : CII 71 (12) (2022)
Haizhu Chen, Yan Qin, Peng Liu, Jianliang Yang, Lin Gui, Xiaohui He, Changgong Zhang, Shengyu Zhou, Liqiang Zhou, Sheng Yang, Yuan-Kai Shi
Genetic Profiling of Diffuse Large B-Cell Lymphoma: A Comparison Between Double-Expressor Lymphoma and Non-Double-Expressor Lymphoma. Molecular diagnosis & therapy (2022)
Liling Huang, Tongji Xie, Fuqiang Zhao, Yu Feng, Hao-Hua Zhu, Le Tang, Xiao-Hong Han, Yuan-Kai Shi
DLX2 Is a Potential Immune-Related Prognostic Indicator Associated with Remodeling of Tumor Microenvironment in Lung Squamous Cell Carcinoma: An Integrated Bioinformatical Analysis. Disease markers 2022 (2022)
Yu Feng, Liling Huang, Haohua Zhu, Le Tang, Xing-Sheng Hu, Yuan-Kai Shi
The exploration of three different treatment models of osimertinib plus antiangiogenic agents in non-small cell lung cancer: A real-world study. Thoracic cancer 13 (18) (2022)
Yuan-Kai Shi, Qingyuan Zhang, Xiaonan Hong, Zhen Wang, Yuhuan Gao, Liqun Zou, Hong Cen, Lin Gui, Yufu Li, Jifeng Feng, Zhao Wang, Mingzhi Zhang, Chuan Jin, Weihua Zhang, Jian-da Hu, Chengyun Zheng, Zhendong Zheng, Liling Zhang, Shaoshui Chen, Yunhong Huang, Yun Tang, Yajie Gao, Miaowang Hao, Xiaoling Li, Chunkang Chang, Haiyan Yang, Hui Wu, Lida Shen, Xiaoyan Ke, Liangming Zhang, Yaming Xi, Linhua Yang, Liangzhi Xie, Wenlin Gai, Yanan Ji
Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthera ® ) in combination with CHOP in patients with previously untreated CD20-positive diffuse large B-cell lymphoma: A randomized, single-blind, phase III clinical trial. Hematological oncology (2022)
Yuan-Kai Shi, Jian Fang, Xuezhi Hao, Shucai Zhang, Yunpeng Liu, Lin Wang, Jianhua Chen, Yi Hu, Xiaosheng Hang, Juan Li, Chunling Liu, Yiping Zhang, Zhehai Wang, Yanping Hu, Kangsheng Gu, Jian'an Huang, Liangming Zhang, Jinlu Shan, Weiwei Ouyang, Yanqiu Zhao, Wu Zhuang, Yan Yu, Jun Zhao, Helong Zhang, Pei Lu, Weidong Li, Meimei Si, Mingjing Ge, Huaize Geng
Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trial. Signal transduction and targeted therapy 7 (1) (2022)
Bo Zhang, Xingya Li, Zhiyong Ma, Shucai Zhang, Xia Song, Hongjun Gao, Liqun Gong, Yi Hu, Mengzhao Wang, Da Jiang, Cuiying Zhang, Xuedong Yuan, Baoshan Cao, Peng Zhang, Ligong Nie, Yuhui Zhang, Xiaoyan Chen, Lei Han, Wenqiang Wei, Yuan-Kai Shi
Prevalence and management of pain in lung cancer patients in northern China: A multicenter cross-sectional study. Thoracic cancer 13 (11) (2022)
Haizhu Chen, Qiaofeng Zhong, Yu Zhou, Yan Qin, Jianliang Yang, Peng Liu, Xiaohui He, Shengyu Zhou, Changgong Zhang, Lin Gui, Sheng Yang, Liqiang Zhou, Yuan-Kai Shi
Enhancement of the International prognostic index with β2-microglobulin, platelet count and red blood cell distribution width: a new prognostic model for diffuse large B-cell lymphoma in the rituximab era. BMC cancer 22 (1) (2022)
Wen Zhang, Xiaohong Han, Lin Yang, Yuanyuan Song, Liangzhi Xie, Wenlin Gai, Yan Wang, Yuan-Kai Shi
Safety, pharmacokinetics and efficacy of SCT200, an anti-EGFR monoclonal antibody in patients with wild-type KRAS/NRAS/BRAF metastatic colorectal cancer: a phase I dose-escalation and dose-expansion study. BMC cancer 22 (1) (2022)
Yu Feng, Le Tang, Hongyu Wang, Yutao Liu, Sheng Yang, Lin Lin, Xingsheng Hu, Yuan-Kai Shi
Immune checkpoint inhibitors combined with angiogenic inhibitors in the treatment of locally advanced or metastatic lung adenocarcinoma patients. Cancer immunology, immunotherapy : CII (2022)
Lin Gui, Shaoyan Liu, Ye Zhang, Yuan-Kai Shi
A Remarkable and Durable Response to Sintilimab and Anlotinib in the First-Line Treatment of an Anaplastic Thyroid Carcinoma without Targetable Genomic Alterations: A Case Report. OncoTargets and therapy 14 (2021)
Jianhua Shi, Guimin Chen, Haitao Wang, Xiuxiu Wang, Bao-Hui Han, Kai Li, Qiming Wang, Li Zhang, Zhehai Wang, Ying Cheng, Jianxing He, Yuan-Kai Shi, Weiqiang Chen, Yi Luo, Lin Wu, Xiuwen Wang, Kejun Nan, Faguang Jin, Jian Dong, Baolan Li, Zhian Liu
Occurrence of hypertension during third-line anlotinib is associated with progression-free survival in patients with squamous cell lung cancer (SCC): A post hoc analysis of the ALTER0303 trial. Thoracic cancer 12 (17) (2021)
Yu Zhou, Shasha Wang, Yunxia Tao, Haizhu Chen, Yan Qin, Xiaohui He, Shengyu Zhou, Peng Liu, Jianliang Yang, Sheng Yang, Lin Gui, Ning Lou, Zhishang Zhang, Jiarui Yao, Xiaohong Han, Yuan-Kai Shi
Low CCL19 expression is associated with adverse clinical outcomes for follicular lymphoma patients treated with chemoimmunotherapy. Journal of translational medicine 19 (1) (2021)
Yan Qin, Haizhu Chen, Peng Liu, Changgong Zhang, Jianliang Yang, Lin Gui, Xiaohui He, Liqiang Zhou, Shengyu Zhou, Shiyu Jiang, Hongxin Jiang, Yuan-Kai Shi
Prognostic value of BCL2 and TP53 genetic alterations for diffuse large B-cell lymphoma patients treated with R-CHOP. Cancer biology & medicine (2021)
Yuan-Kai Shi, Kaijian Lei, Yuming Jia, Bingqiang Ni, Zhiyong He, Minghong Bi, Xicheng Wang, Jianhua Shi, Ming Zhou, Qian Sun, Guolei Wang, Dongji Chen, Yongqian Shu, Lianke Liu, Zhongliang Guo, Yong Liu, Junquan Yang, Ke Wang, Ke Xiao, Lin Wu, Tienan Yi, Debin Sun, Mafei Kang, Tianjiang Ma, Yimin Mao, Jinsheng Shi, Tiegang Tang, Yan Wang, Puyuan Xing, Dongqing Lv, Wangjun Liao, Zhiguo Luo, Bin Wang, Xiaohong Wu, Xiaoli Zhu, Shuhua Han, Qisen Guo, Rongyu Liu, Zhiwei Lu, Jianyong Zhang, Jian Fang, Changlu Hu, Yinghua Ji, Guolong Liu, Hong Lu, Dedong Wu, Junhong Zhang, Shuyang Zhu, Zheng Liu, Wensheng Qiu, Feng Ye, Yan Yu, Yanqiu Zhao, Qinhong Zheng, Jun Chen, Zhanyu Pan, Yiping Zhang, Wenjuan Lian, Bo Jiang, Bo Qiu, Guojun Zhang, Hua Zhang, Yanju Chen, Yuan Chen, Hongbing Duan, Manxiang Li, Shengming Liu, Lijun Ma, Hongming Pan, Xia Yuan, Xueli Yuan, Yulong Zheng, Emei Gao, Li Zhao, Shumin Wang, Can Wu
Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non-small-cell lung cancer: A multicenter, randomized, double-blinded, phase III trial. Cancer communications (London, England) 41 (9) (2021)
Qiaoyun Tan, Liyuan Dai, Yanrong Wang, Shuxia Liu, Te Liang, Rongrong Luo, Shasha Wang, Ning Lou, Haizhu Chen, Yu Zhou, Qiaofeng Zhong, Jianliang Yang, Puyuan Xing, Xingsheng Hu, Yutao Liu, Shengyu Zhou, Jiarui Yao, Di Wu, Zhishang Zhang, Le Tang, Xiaobo Yu, Xiaohong Han, Yuan-Kai Shi
Anti-PD1/PDL1 IgG subclass distribution in ten cancer types and anti-PD1 IgG4 as biomarker for the long time survival in NSCLC with anti-PD1 therapy. Cancer immunology, immunotherapy : CII (2021)
Li-Ling Huang, Xing-Sheng Hu, Yan Wang, Jun-Ling Li, Hong-Yu Wang, Peng Liu, Jian-Ping Xu, Xiao-Hui He, Xue-Zhi Hao, Pei-Di Jiang, Yu-Tao Liu, Jian Luo, Sheng-Yu Zhou, Jin-Wan Wang, Jian-Liang Yang, Yan Qin, Peng Yuan, Lin Lin, Yuan-Kai Shi
Survival and pretreatment prognostic factors for extensive-stage small cell lung cancer: A comprehensive analysis of 358 patients. Thoracic cancer 12 (13) (2021)
Yi Ba, Yuan-Kai Shi, Wenqi Jiang, Jifeng Feng, Ying Cheng, Li Xiao, Qingyuan Zhang, Wensheng Qiu, Binghe Xu, Ruihua Xu, Bo Shen, Zhiguo Luo, Xiaodong Xie, Jianhua Chang, Mengzhao Wang, Yufu Li, Yuerong Shuang, Zuoxing Niu, Bo Liu, Jun Zhang, Li Zhang, Herui Yao, Conghua Xie, Huiqiang Huang, Wangjun Liao, Gongyan Chen, Xiaotian Zhang, Hanxiang An, Yanhong Deng, Ping Gong, Jianping Xiong, Qinghua Yao, Xin An, Cheng Chen, Yanxia Shi, Jialei Wang, Xiaohua Wang, Zhiqiang Wang, Puyuan Xing, Sheng Yang, Chenfei Zhou
Current management of chemotherapy-induced neutropenia in adults: key points and new challenges: Committee of Neoplastic Supportive-Care (CONS), China Anti-Cancer Association Committee of Clinical Chemotherapy, China Anti-Cancer Association. Cancer biology & medicine 17 (4) (2020)
Haizhu Chen, Daquan Wang, Qiaofeng Zhong, Yunxia Tao, Yu Zhou, Yuan-Kai Shi
Pretreatment body mass index and clinical outcomes in cancer patients following immune checkpoint inhibitors: a systematic review and meta-analysis. Cancer immunology, immunotherapy : CII 69 (12) (2020)
Yan Qin, Shiyu Jiang, Peng Liu, Jianliang Yang, Sheng Yang, Xiaohui He, Shengyu Zhou, Lin Gui, Jing Lin, Xinhua Du, Yuting Yi, Yan Sun, Yuan-Kai Shi
Characteristics and Management of TP53-Mutated Diffuse Large B-Cell Lymphoma Patients. Cancer management and research 12 (2020)
Xiaohong Han, Ying Han, Qiaoyun Tan, Yu Huang, Jianliang Yang, Sheng Yang, Xiaohui He, Shengyu Zhou, Yan Song, Jinping Pi, Lijie Zuo, Jiarui Yao, Di Wu, Zhishang Zhang, Yuan-Kai Shi
Tracking longitudinal genetic changes of circulating tumor DNA (ctDNA) in advanced Lung adenocarcinoma treated with chemotherapy. Journal of translational medicine 17 (1) (2019)
Xiao-Yan Si, Li Zhang, Hanping Wang, Xiaotong Zhang, Mengzhao Wang, Baohui Han, Kai Li, Qiming Wang, Jianhua Shi, Zhehai Wang, Ying Cheng, Yuan-Kai Shi, Weiqiang Chen, Xiuwen Wang, Yi Luo, Kejun Nan, Faguang Jin
Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303. Thoracic cancer 10 (3) (2019)
Shengyu Zhou, Xingsheng Hu, Yan Wang, Junling Li, Liqiang Zhou, Xuezhi Hao, Yutao Liu, Yuan-Kai Shi
Clinicopathologic characteristics and outcome of patients with different EGFR mutations. Asia-Pacific journal of clinical oncology 15 (3) (2018)
Carlo Gambacorti-Passerini, Sergey Orlov, Li Zhang, Fadi Braiteh, Huiqiang Huang, Taito Esaki, Keizo Horibe, Jin-Seok Ahn, Joseph T Beck, William Jeffrey Edenfield, Yuan-Kai Shi, Matthew Taylor, Kenji Tamura, Brian A Van Tine, Shang-Ju Wu, Jolanda Paolini, Paulina Selaru, Tae Min Kim
Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study. American journal of hematology 93 (5) (2018)

Yuan-Kai Shi.css-eqlu8i{font-size:small;padding-left:4px;} (Yuankai Shi)

Publication Activity (10 Years)

Top Topics

Top Venues

Yuan-Kai Shi (Yuankai Shi)